SCHEMBL6020879

SCHEMBL6020879

CC(C)COC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCCC#N

nearest known ligand 0.79

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NMBR P28336 14/20 0.79
TACR1 P25103 1/20 0.79
MAPT P10636 3/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
CTSL P07711 2/20 0.62
CTSS P25774 1/20 0.62
CTSK P43235 1/20 0.62
TACR3 P29371 1/20 0.62
GAA P10253 1/20 0.57
HTT P42858 1/20 0.57
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6020364 0.92 NMBR (0.77) NMBRTACR1MAPTSMN1; SMN2CTSL
SCHEMBL6019326 0.91 NMBR (0.65) NMBRTACR1MAPTCTSLCTSS
SCHEMBL6020882 0.90 NMBR (0.66) NMBRTACR1MAPTCTSLCTSS
SCHEMBL6020628 0.89 CTSL (0.68) NMBRTACR1MAPTCTSLCTSS
SCHEMBL6020210 0.87 NMBR (0.66) NMBRTACR1MAPTCTSLCTSS
SCHEMBL6019142 0.86 NMBR (0.65) NMBRTACR1MAPTCTSLCTSS
SCHEMBL6021231 0.86 CTSL (0.84) NMBRTACR1MAPTSMN1; SMN2CTSL
SCHEMBL6020039 0.86 NMBR (0.66) NMBRTACR1MAPTCTSLCTSS
SCHEMBL6020884 0.86 NMBR (0.71) NMBRTACR1MAPTSMN1; SMN2CTSL
SCHEMBL6021350 0.85 CTSL (0.66) NMBRTACR1MAPTSMN1; SMN2CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US claimed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 EP claimed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 WO claimed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP claimed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP claimed
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US disclosed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 EP disclosed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 WO disclosed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP disclosed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252813-A1 Apparatus for curing a composite laminate DHX29, HDHD5, DHRS9 NMBR 2003/4885TACR1 3501/4885MAPT 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.